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Earlier studies on HIV-1 strains from HIV-1-infected long-term nonprogressors (LTNP) have reported that nef deletions
and/or attenuations may be crucial in the survival of these patients. Other reports have suggested that the nef gene may
not be the only gene involved, but attenuations in other accessory genes (vif, vpr, vpu), which play an important role in the
viral life cycle, may be similarly important in chronic HIV-1 infection in LTNPs. Here we show the molecular and phylogenetic
analyses of the vpr gene in HIV-1 strains derived from both blood and plasma of an HIV-1 infected long-surviving mother–
child pair which has survived for 13 years with HIV infection: both have maintained stable CD4/ T-cell counts. Analyses
of blood- and plasma-derived HIV-1 vpr clones indicated the presence of defects (insertions and deletions) and length
polymorphisms. Interestingly, all the vpr defects in PBMCs and plasma were clustered at the C-terminus of the Vpr protein,
between amino acid residues 83 and 89, which has been implicated in the G2 cell cycle arrest as a step to early HIV-1
infection. In contrast, the vpr sequence analysis of HIV-1 strains derived from 30 different patients, who either died of AIDS-
related illnesses or have AIDS, showed neither C-terminal defects nor length polymorphism in the vpr gene. Also, secondary
structure predictions suggest that the naturally occurring mutations at the C-terminal region (aa 83–89) have the potential
to affect the secondary structure of the Vpr protein. Also, in some cases, the out-of-frame mutations and the length
polymorphisms affect the tat gene reading frame. Together, these mutations may have potential significance in conferring
chronic HIV-1 infection in this long-surviving nonprogressing mother–child pair. q 1996 Academic Press, Inc.
Human immunodeficiency virus type 1 (HIV-1) is the cells, whereas normal Vpr is known to increase the rate
etiologic agent of acquired immunodeficiency syndrome of viral replication and cytopathic effects of the virus in
(AIDS) (1). Experimental evidence from simian and hu- cell culture (14, 15). Furthermore, expression of Vpr alone
man immunodeficiency virus (SIV and HIV), respectively, may affect the progression of cells in the cell cycle (16).
has suggested that attenuations in the nef gene of HIV- In an interesting finding Weiner and co-investigators (11)
1 derived from infected long-term survivors or nonprog- suggested that extracellular Vpr protein can increase cel-
ressors (LTNPs) are critical in providing protection in vivo lular permissiveness to HIV-1 replication and reactivate
(2, 3–9). In addition, recent data suggest that attenua- virus from latency. The same group also showed that
tions in other accessory genes such as vpr, vif, rev, and serum Vpr could also activate virus expression from rest-
tat may also be participating in providing natural protec- ing PBMCs of HIV-1-infected individuals. Thus, Vpr may
tion to HIV-1-infected LTNPs (8–10). The Vpr protein, have the potential to participate in the activation of repli-
which is primarily localized in the nucleus of infected cation and controlling latency of HIV-1 in vivo (17).
cells (11, 12), can be immunogenic with 30–40% of HIV- According to several recent reports (18, 19), Vpr is
1-infected individuals, demonstrating anti-Vpr antibodies involved in G2 cell cycle arrest and inducing cytoskeletal
(13). Recently, the mutated vpr gene has been suggested changes as a step to early HIV-1 infection. Recently, it
in readily establishing long-term chronic infection of T has also been demonstrated that the N-terminal domain
of Vpr is involved in the nuclear localization (20, 21) and
the incorporation of Vpr into HIV-1 virions (22, 16),1 To whom correspondence and reprint requests should be ad-
whereas the C-terminus is crucial in G2 cell cycle arrestdressed. Fax: 61-2 (639 7431). E-mail: Nitins@Westmed.WH.SU.
EDU.AU. (18). Therefore, it is likely that mutations at the C-terminus
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may have the potential to alter and/or mute the G2 phase antigen. Furthermore, the cultures were assayed for par-
ticle-associated reverse transcriptase (RT) activity andarresting signal, which could lead to chronic HIV infec-
tion. also for integrated proviral DNA copies by the polymer-
ase chain reaction (PCR).Although the mechanisms that allow for long-term sur-
vival in HIV-1-infected LTNPs are not understood, it is For the genetic analyses, DNA was extracted from
fresh PBMCs (5 1 106 cells) using a QIA-Amp bloodlikely that controlled viral replication of HIV-1 strains in
LTNPs and the hosts’ immunological make-up are in- extraction kit (Quiagen, Germany) as per the manufactur-
er’s instructions. One microgram of column-purified DNAvolved (23 – 31). In this context, the role of viral gene
attenuations in conferring protection cannot be underes- was used for PCR with vpr-specific external primers (vpr-
ext-1 5*TAACAGAAGATAGATGGAAC3 * with vpr int-2).timated; it is likely that the attenuations are partially re-
sponsible for rendering the virus noninfectious by slow- The reaction with external primers was run for 25 cycles,
and 5 ml of this was then subjected to further amplifica-ing the replication. Given the above functions and also
the role of the C-terminal region of Vpr in G2 cell cycle tion with the internal primers (vpr-int-1 5*ATGGAACAA-
GCCCCAGAAGACCAGGGCC3* and vpr-int-2 5*TAG-arrest, Vpr is an attractive candidate for studying its role
in LTNPs or chronic HIV-1 infection. GCTGACTTCCTGGATGCTTCTTCCAGGGCTCTA 3* ) for
30 amplification cycles. The PCR conditions for both re-In an attempt to elucidate the molecular mechanisms
for long-term survival in HIV-1-infected individuals, we actions were 947 for 3 min, 557 for 1 min; 727 for 2 min
(1 cycle); 947 for 1 min; 557 for 30 sec; 727 for 2 min (withhave dissected the quasispecies of the vpr gene of HIV-
1 derived from PBMCs and plasma of the first mother 25 and 30 cycles, respectively).
Extraction of RNA from plasma was done by subjecting(LW) and child (JW) pair which has survived for13 years
with HIV-1 infection. They have no apparent sign of AIDS- plasma for virus pelleting by ultracentrifugation at
100,000 rpm for 1 hr. Viral pellets were resuspended inrelated illness and have maintained stable CD4/ T-cell
counts (700 and 750/ml blood, respectively) from 1983 to lysis buffer (5 M guanidium thiocyanate, sodium citrate,
sarcosyl, 2-mercaptoethanol), phenol:chloroform ex-1995. The mother was infected via blood transfusion,
while pregnant, and in 1983 was confirmed positive by tracted, and isopropanol precipitated (32). Following cen-
trifugation at 15,000 rpm for 15 min, pellets were washedELISA. At the end of 1983, she had a baby boy who
was uninfected at the time of birth. In 1984, the baby twice with 70% ethanol and dried, and the viral RNA
was resuspended in 10 ml of DEPC-treated water. Tencontracted the HIV-1 infection via breast feeding and
tested positive for anti-HIV-1 antibodies. The PBMC sam- milliliters of plasma-derived RNA was reverse tran-
scribed for 1 hr at 427 in 50 mM Tris–HCl (pH 8.3), 50ples available to us were from 1987, 1989, 1992, 1993,
1994, and 1995, whereas the plasma samples available mM KCl, 10 mM MgCl2 , 0.5 mM spermidine, 10 mM DTT,
5 mM dNTPs, 5 pm/ml random hexamers (Boeringerwere only from 1994 and 1995. This report is novel with
respect to its first description of a HIV-1-infected long- Mannheim, Germany), 0.5 ml of RNAsin (Pharmacia, Swe-
den), 0.5 ml of AMV reverse transcriptase (Gibco BRL).surviving mother–child pair. Here we describe a detailed
picture of HIV-1 vpr quasispecies evolution in PBMCs For cDNA amplification, the aforementioned conditions
were used with vpr external and internal primers.(collected in 1987, 1989, 1992, 1993, 1994, and 1995) and
in plasma (collected in 1994 and 1995), along with the The PBMC- and plasma-derived PCR products were
run on 1% agarose (Promega). The gel was visualizedsecondary-structure analysis of Vpr protein and its possi-
ble implications on chronic HIV-1 infection. under UV light and was subsequently transferred over-
night by alkali denaturation onto a nylon membrane (DuPatients’ blood was collected into acid citrate tubes
and was subjected to Ficoll–Hypaque gradient centrifu- Pont). The membrane was prehybridized for 2 hr at 427
and hybridized overnight at 427 by using [g-32P]ATP-gation at 1000 g for 10 min within 3 hr of collection.
Peripheral blood mononuclear cells were separated, and labeled probe vpr det/ (5* AGAAGACCAGGGGCCACA-
GAGGGAGCC 3 *). The membrane was washed in 21the plasma was further subjected to centrifugation for 20
min in order to eliminate any residual cells. These fresh SSC and 0.1% SDS at 657 and autoradiographed over-
night using Hyperfilm (Amersham, UK). For cloning, thePBMCs from both mother (LW) and child (JW) were used
in virus co-culture studies. For these, we employed 5 1 PCR-amplified products were ligated into pGEM-T vector
(Promega) as per the manufacturer’s protocol. Fifty micro-106 fresh PBMCs from patients LW and JW, respectively,
with an equal number of uninfected PBMCs that had liters of competent Escherichia coli cells (strain JM109)
were transformed using 4 ml of ligation mix. The recombi-been stimulated with PHA and IL-2 for 48–72 hr. These
standard cultures were maintained as per the AIDS clini- nants were plated on Luria broth–agar with ampicillin
(75 mg/ml) containing 50 ml of X-gal (40 mg/ml) and 20cal trials group (ACTG) consensus protocol at the West-
mead Hospital. The cultures were maintained by two ml of IPTG (100 mg/ml), and incubated overnight at 377.
The recombinants were transferred onto nylon filters, fol-weekly passages with fresh PBMCs for at least 8–11
weeks. Co-cultures were routinely maintained at 3-day lowed by alkaline denaturation and neutralization, with
subsequent hybridization with [g-32P]ATP-labeled vprintervals for viral replication by the measurement of p24
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probe. The positive clones were streaked onto the fresh changes in HIV-1 MPV5180 occur at the same position
where we have observed insertions, deletions, or baseplates for further purification and the single colonies
were picked and cultured overnight at 377 in Luria broth substitutions in the HIV-1 strains. Analysis of these HIV-
1 strains in the V3 region has previously indicated thatwith ampicillin at 377 under vigorous shaking. The bacte-
rial cells were pelleted and the DNA was extracted as they belong to subtype B, and minimal length polymor-
phism is seen in the vpr gene of subtype B HIV-1 isolatespreviously described (33). The purified vpr clones were
sequenced with [a-35S]dATP (Amersham, Australia) by (38, 39).
In addition, we have also analyzed HIV-1 vpr genethe dideoxy chain-termination method using the Seque-
nase version 2.0 kit (Amersham-USB). The sequencing peptide sequences directly from PBMCs of 30 other pa-
tients (which includes male and female patients, non-reactions were run on 6% Sequagel (National Diagnos-
tics), and then the gel was dried and autoradiographed transmitting and transmitting mothers and children) who
died of AIDS or have AIDS-related illnesses. Comparisonovernight.
Multiple sequence and peptide alignments were gen- of the C-terminal Vpr sequences clearly suggested that
HIV-1 strains derived from these patients neither haveerated by using software available from the GCG pack-
age; the secondary structure predictions and hydropathi- any abnormality nor do they exhibit length polymorphism
(Fig. 2D), as observed in the DNA and RNA clones de-city profiles were generated by using the Chou and Fas-
man algorithm (34) and Kyte and Doolittle predictions rived from both long-surviving HIV-1 infected mother (LW)
and child (JW). So far, we have seen C-terminal mutations(GCG package) (35), respectively. The average mass of
Vpr protein was calculated by using software DNA 1.8 only in 3 HIV-1 infected intravenous drug users, but a
detailed analysis viral quasispecies did not show pre-(Frederic Dardel, France). Phylogenetic relationships
were studied using CLUSTAL (36, 37) and trees were dominance of such mutations in vivo (10).
Peptide sequence comparisons of the clones derivedbootstrapped with 1000 replications.
Coculture studies of fresh PBMCs from both mother from PBMCs and plasma of both mother (LW) and child
(JW) indicated that a compartmentalization occurred be-and child showed that the mother and child were culture
positive for HIV-1, and even after 8 weeks of culture tween PBMC and plasma-derived vpr clones. Interest-
ingly, a major difference between the PBMC- (1987, 1989,no cytopathic effect was observed. These findings are
consistent with other studies (3, 9, 24) in which no recov- 1991, 1993, 1994, and 1995) (Fig. 2A) and plasma- (1994
and 1995) derived vpr clones (Fig. 2B) is the occurrenceerable infectious virus was detectable in the cells from
people who have survived with HIV-1 infection for 13 of fewer defects at the C-terminus region of the Vpr pro-
tein in plasma with the peptide length of 95 amino acidsyears. Although the mother and child harbor replication-
competent strains of HIV-1, it is clear that the HIV-1 caused by an in-frame deletion of an arginine (R-88).
Also, the plasma-derived clones are more homogeneousstrains from both mother and child lack the ability for
cellular permissiveness required for productive HIV-1 in- as regards the genetic variation in their vpr genes. The
only unique changes in plasma RNA clones was a dele-fection.
We could successfully amplify the 291-bp vpr fragment tion of alanine at position 89 in 9 of 13 clones. In contrast,
the PBMC-derived vpr clones showed a greater variationfrom the PBMCs (collected in 1987, 1989, 1991, 1993,
1994, and 1995) (Fig. 1A) and plasma (collected in 1994 at the C-terminus, with in-frame insertions or deletions
causing considerable length polymorphism in the Vprand 1995) (Fig. 1B) of both mother and child. Sequencing
of vpr revealed that most changes were clustered in the protein. In PBMCs, the Vpr peptide length ranged from
95 to 98 aa. Interestingly, in 1987 a PBMC-derived Vprbasic amino acid-rich domain (aa residues 83–96), which
was most susceptible to in-frame insertions, deletions, clone from the mother (Iw87-1b) had a 5-bp out-of-frame
insertion (Fig. 1A). Also, several signature changes, be-out-of-frame deletions, and nonconservative base substi-
tutions (10). These changes resulted in length polymor- tween PBMCs and plasma-derived clones, were also
identified at amino acid residues 28, 37, 41, 55, 77, andphism in the vpr gene in both PBMC- and plasma-derived
vpr clones, and as a consequence, average molecular 83 (Figs. 2A and 2B).
Dissection of the RNA and DNA clones by phyloge-mass of Vpr protein was affected. Although the amino
acid changes that are distributed over the entire length netic analysis suggests that both vpr plasma RNA and
PBMC DNA clones are not related in time. Additionally,of the Vpr protein sequence before aa residue 83, they
do not have the potential to modulate the length polymor- the analysis of 13 vpr RNA clones in 1994 and 1995
from both mother and child showed separate branchingphism and molecular mass of the Vpr protein (Figs. 2A
and 2B). The most commonly reported Vpr length is 96 patterns, along with the intermingling of 1994 and 1995
vpr clones (data not shown).aa. However, there are two HIV-1 sequences described
with length polymorphism in the vpr gene (38). Only HIV- The vpr clones derived from PBMC DNA of both mother
and child from 1987, 1989, 1991, 1993, 1994, and 19951 MPV5180 has a 9-bp insertion, which results in 3 addi-
tional amino acids (SNT) being included in the protein, indicated a more complex pattern of divergence between
clones derived from different years. The interspersed pat-and it belongs to subtype O (based on the vpr gene). The
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FIG. 1. (A) The hybridization of vpr gene PCR products derived from PBMCs of mother (LW) and child (JW). The products were hybridized with a
[g-32P]dATP labeled Vpr det/ probe. PC is primer control. (B) The hybridization of vpr gene PCR products derived from plasma of mother (LW) and
child (JW). The products were hybridized with [g-32P]ATP-labeled vpr det/ probe. PC is primer control.
tern of PBMC-derived clones on the phylogenetic tree child, it is likely that the source of virus in plasma may be
a subset of transcriptionally active CD4/ lymphocytes,further suggested a strong interrelationship between var-
ious vpr clones and the HIV-1 strains from both mother or virus could be secreted into the circulation by cells
sequestered in solid tissue. Previously, it had beenand child (data not shown). A more pronounced pattern
of intermixing of PBMC-derived clones could be due to shown that plasma from both asymptomatic and symp-
tomatic individuals is infectious (41) and that infection ofthe evolution of the same viral quasispecies in vivo from
1987 to 1985, which was transmitted from mother to child. PBMCs may be a self-sustaining process. Infection, and
continued sequence evolution of HIV, may indeed takeCombined analysis of RNA and DNA vpr clones indi-
cated an interesting pattern of segregation between plas- place in peripheral CD4/ lymphocytes. A similar trend
of in vivo evolution of vpr quasispecies was also evidentma- (collected in 1994 and 1995) and PBMC- (collected in
1987, 1989, 1991, 1993, 1994, and 1995) derived clones. from our analyses.
Secondary structure predictions of the amino acid resi-Interestingly, the plasma-derived clones were more ge-
netically related to the PBMC-derived clones only in dues (77–96) at the C-terminus of Vpr, using the Chou
and Fasman algorithm (34), also suggested that the natu-1991, 1993, 1994, and 1995, whereas the PBMC vpr
clones derived in 1987 and 1989 diverged earlier (Fig. rally occurring mutations (insertions, deletions, and sub-
stitutions) between aa residues 83 and 89 have a pro-3). This may be due to greater diversity in earlier PBMC
DNA clones, but we do not have plasma RNA clones to found effect on the secondary structure of Vpr protein
(Fig. 4) (10). Mutational changes mostly affected b-turns,validate this.
In this HIV-1-infected nonprogressing mother–child which are crucial in structural stabilization of the protein.
Furthermore, our peptide comparisons suggest that 62%pair, we could find a definitive correlation between trans-
mission and genetic homogeneity in the vpr. This is in of PBMC-derived clones showed an introduction of a
proline at residues 85 and 87, replacing the highlycontrast to the V3 region, which undergoes selection,
and previously no correlation was found between degree charged arginines at these positions. In contrast, 69% of
plasma-derived clones showed the occurrence of theof heterogeneity in V3 and transmission strains between
mother and child (40). introduction of prolines at positions 85 and 87 (Fig. 2B).
It will be recalled that the protein linkages of the nitrogenIn some cases the HIV-1 RNA population of the mother
was more related to the HIV-1 RNA population of the atom in proline consists of imido groups ({CO{N|)
instead of amino groups ({CO{NH|) formed by allchild, whereas in other cases it was more related to the
virus DNA population (Fig. 2A), suggesting that either other amino acids. The nitrogen group in proline is thus
unable to form the crucial hydrogen bond, having nocell-free or cell-associated virus may have been transmit-
ted. Based on this genetic relationship between plasma hydrogen available for the purpose. As a result, proline
will mark a sudden bend in the axis of the coil (42).RNA and PBMC DNA vpr clones from both mother and
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FIG. 2. The peptide alignment of PBMC-derived clones of the vpr gene. Boxed areas are various functional domains within the Vpr protein. DPM
is a dipeptide motif; # indicates residues participating in leucine zipper formation; - - - indicates deletions; * denotes stop codon; and pNL43 is the
HIV-1 prototype sequence. (B) The peptide alignment of plasma-derived RNA clones of the Vpr protein. (C) Peptide sequence of Vpr showing four
leucine zipper motifs (LZM) (LxxxxxxL) located between amino acid residues 53 and 74. Leucine or isoleucine participates in LZM formation. (D)
C-terminus (aa 81–96) peptide alignment of 30 HIV-1 Vpr sequences derived from the PBMCs of patients who died of AIDS-related illnesses or
who have AIDS. For genetic comparisons of the C-terminus sequences of the Vpr peptide sequence, we have chosen three HIV-1 infected groups:
(i) male and female patients, (ii) mother and child pairs, and (iii) nontransmitting mothers, respectively.
228
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FIG. 2—Continued
Previously (42) proline rings have been found at places macrophage infection (44–46), it may be that these natu-
rally occurring mutations at the 3 * end of the vpr genein the hemoglobin molecule where the chain changes
direction and abandons the helix (43). Interestingly, the of HIV-1 derived from both mother and child may have
relevance in the chronicity of HIV-1 infection. Further-clones which did not show the introduction of prolines
revealed amino acid substitutions at position 70, which more, a comparison of Vpr C-terminal sequences of HIV-
1 strains derived from 30 different patients (includingis crucial in the formation of leucine zipper motif
(LxxxxxxL) (Fig. 2C). This naturally occurring mutation male and female patients, mother–child pairs, and non-
HIV transmitting mothers, who either died of AIDS-related(residue 70 I r V or T) alters the zipper located between
residues 60 and 81 from ILQQLLFI r ILQQLLFT or V (Fig. illnesses or have AIDS) lends further credence to the
importance and specificity of these changes at the C-2A). Leucine zipper motifs (LZM), which are formed by
the participation of both leucine and isoleucine residues, terminus of the vpr gene derived from the long-surviving
mother–child pair.are found commonly in DNA-binding proteins or tran-
scriptional activators (28). Usually, leucine zipper motifs Our in vitro culture studies suggest that the viral strains
from both mother and child transiently infected T-cells,reveal a tight evolutionary conservation in the vpr gene
of the previously reported HIV-1 isolates/subtypes (38). and they lack the ability for productive HIV-1 infection.
Furthermore, the cells that have survived infection withPreviously, it has been suggested that the leucine/isoleu-
cine-rich domain (aa 60 –75) may impart to Vpr a weak HIV may therefore be due to highly selected subset of
the infecting virus strains (originating in the course oftranscriptional activity (21). Moreover, Vpr is regarded as
a weak transcriptional activator, and any mutations in evolution of viral quasispecies in vivo), whose noncyto-
pathic properties ensure the long-term survival of thisthe leucines or isoleucines abolish the functional activity
of Vpr (12). mother–child pair. These infecting strains are predomi-
nant in vivo (62%) and show defects at the C-terminalIn the light of a recent evidence regarding the muta-
tions in the vpr gene can cause chronic HIV-1 infection region of the Vpr, along with enormous polymorphism in
the length of Vpr resulting from these mutations at the C-(18), and also the role of C-terminal amino acid residues
(aa 83–90) in G2 cell cycle arrest during HIV-1 infection, terminal end in both PBMC- and plasma-derived clones.
Recently, it has been suggested that for HIV-1 pathogen-it is likely that these mutations occurring between resi-
dues 83 and 89 may, in part, be responsible for chronic esis in vivo, the ratio and/or the balance between the
defective and nondefective clones may play an importantinfection in this mother–child pair, which has survived
for 13 years with stable CD4/ T-cell counts. Since Vpr part. This is consistent with previous studies (8) which
suggest that 60% defective HIV-1 clones in the acces-protein is also known to participate in productive human
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FIG. 4. The secondary structure predictions based on the defects clustered at the C-terminus of the vpr gene. Only basic amino acid-rich region
(aa 81–96) was analyzed. B, b-sheet; b, propensity for b-sheet; T, b-turn; t, propensity for b-turn; h, propensity for a-helix. (*) is neutral change.
pNL43 is the HIV-1 prototypic isolate. The far right end shows the total Vpr peptide length in each case.
sory/regulatory genes (vif, vpr, nef, vpu, and tat) play an lies at the C-terminal region of the vpr gene, it is likely
that mutations (in some cases) may further affect the tatimportant part in conferring long-term protection in
LTNPs. gene open reading frame. It should be recalled that Tat
is a transcriptional co-activator and plays a vital role inInterestingly, our previous work on the HIV-1 nef gene
from both mother and child suggested that 80% popula- regulating translation (47).
These are the first analyses of the vpr gene in a long-tion of nef gene population was open in PBMC-derived
clones, but prematurely terminated by only one amino surviving genetically linked mother–child pair, and they
suggest an avenue for further study. No reports haveacid. The remaining 20% of the total DNA clones showed
random deletions in the nef gene ranging between 200 defined the biological role of these mutations in G2 cell
cycle arrest by HIV-1; only in vitro analyses could explainand 350 bp (9). In contrast, 100% RNA clones were open
but they too terminated prematurely by one amino acid. if these mutations really form the basis for chronic HIV-
1 in this mother–child pair. In summary, these studiesIn both cases, terminal cysteine (cys-206) was eliminated
by an ochre stop codon (9). These data further suggest will continue to provide deeper insights into molecular
mechanisms of HIV-1 pathogenesis in vivo.that the most likely scenario for the long-term survival of
this mother–child pair with chronic HIV-1 infection could
be due to predominance of defects in the vpr gene quasi- ACKNOWLEDGMENTS
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